{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:34:11Z","timestamp":1784554451115,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ebiom.2022.104297","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T05:41:23Z","timestamp":1664862083000},"page":"104297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core"],"prefix":"10.1016","volume":"85","author":[{"given":"Rui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-0693","authenticated-orcid":false,"given":"Yong-Gang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7873","key":"10.1016\/j.ebiom.2022.104297_bib0001","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: perspectives on the future trajectory of COVID-19","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104297_bib0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2022.104297_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0004","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/jmv.26817","article-title":"Co-infection of influenza A virus and SARS-CoV-2: a retrospective cohort study","volume":"93","author":"Cheng","year":"2021","journal-title":"J Med Virol"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104297_bib0005","article-title":"A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2","volume":"8","author":"Zhang","year":"2021","journal-title":"Natl Sci Rev"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104297_bib0006","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ije\/dyab081","article-title":"Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design","volume":"50","author":"Stowe","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"10296","key":"10.1016\/j.ebiom.2022.104297_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104297_bib0008","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104297_bib0009","first-page":"e2313","article-title":"Hadj Hassine I. Covid-19 vaccines and variants of concern: a review","year":"2021","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104297_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgg.2021.02.006","article-title":"COVID-19 mRNA vaccines","volume":"48","author":"Huang","year":"2021","journal-title":"J Genet Genom"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104297_bib0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2022.104297_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/2515135520908121","article-title":"Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing","volume":"8","author":"Rajaram","year":"2020","journal-title":"Therap Adv Vaccines Immunother"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104297_bib0013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.chom.2021.02.002","article-title":"Virus vaccines: proteins prefer prolines","volume":"29","author":"Sanders","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104297_bib0014","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common features of enveloped viruses and implications for immunogen design for next-generation vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104297_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0016","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41467-021-21037-2","article-title":"A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2","volume":"12","author":"Huang","year":"2021","journal-title":"Nat Commun"},{"issue":"7819","key":"10.1016\/j.ebiom.2022.104297_bib0017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-022-00879-2","article-title":"A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants","volume":"7","author":"Duan","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104297_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104297_bib0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41422-021-00531-8","article-title":"Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0021","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/s41467-021-23942-y","article-title":"SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung","volume":"12","author":"Routhu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0022","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41467-020-20654-7","article-title":"A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses","volume":"12","author":"Tan","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104297_bib0024","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/vaccines9040395","article-title":"Development of a vaccine against SARS-CoV-2 based on the receptor-binding domain displayed on virus-like particles","volume":"9","author":"Zha","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104297_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/08923973.2016.1165246","article-title":"The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines","volume":"38","author":"McCluskie","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"33","key":"10.1016\/j.ebiom.2022.104297_bib0026","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2010.02.103","article-title":"Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies","volume":"28","author":"Jegerlehner","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/v12050488","article-title":"Virus-like particles as an immunogenic platform for cancer vaccines","volume":"12","author":"Caldeira","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0028","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/22221751.2020.1770631","article-title":"Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microb Infect"},{"issue":"44","key":"10.1016\/j.ebiom.2022.104297_bib0029","doi-asserted-by":"crossref","first-page":"18979","DOI":"10.1073\/pnas.1013387107","article-title":"Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Nat Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.24272\/j.issn.2095-8137.2020.053","article-title":"COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2","volume":"41","author":"Xu","year":"2020","journal-title":"Zool Res"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.24272\/j.issn.2095-8137.2020.202","article-title":"Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques","volume":"41","author":"Song","year":"2020","journal-title":"Zool Res"},{"issue":"6483","key":"10.1016\/j.ebiom.2022.104297_bib0032","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.ebiom.2022.104297_bib0033","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/JVI.00420-14","article-title":"Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses","volume":"88","author":"Iba","year":"2014","journal-title":"J Virol"},{"issue":"22","key":"10.1016\/j.ebiom.2022.104297_bib0034","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1128\/JVI.01388-13","article-title":"Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site","volume":"87","author":"Hong","year":"2013","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0035","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41598-019-40937-4","article-title":"An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"41","key":"10.1016\/j.ebiom.2022.104297_bib0036","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1016\/j.vaccine.2019.08.043","article-title":"Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects","volume":"37","author":"Zhao","year":"2019","journal-title":"Vaccine"},{"issue":"6373","key":"10.1016\/j.ebiom.2022.104297_bib0037","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aan8806","article-title":"Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design","volume":"359","author":"Du","year":"2018","journal-title":"Science"},{"issue":"7830","key":"10.1016\/j.ebiom.2022.104297_bib0038","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.ebiom.2022.104297_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.029","article-title":"Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2","volume":"185","author":"Xu","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0041","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s42826-020-00078-6","article-title":"The 'R' principles in laboratory animal experiments","volume":"36","author":"Lee","year":"2020","journal-title":"Lab Anim Res"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104297_bib0042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J Pharmacol Pharmacotherap"},{"issue":"13","key":"10.1016\/j.ebiom.2022.104297_bib0043","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.ebiom.2022.104297_bib0044","article-title":"Particulate alum via pickering emulsion for an enhanced COVID-19 vaccine adjuvant","volume":"32","author":"Peng","year":"2020","journal-title":"Adv Mater"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104297_bib0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infects Diseases"},{"issue":"6510","key":"10.1016\/j.ebiom.2022.104297_bib0046","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104297_bib0047","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41421-021-00331-9","article-title":"Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice","volume":"7","author":"Tian","year":"2021","journal-title":"Cell Discov"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104297_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104297_bib0050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41422-021-00514-9","article-title":"Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines","volume":"31","author":"Cao","year":"2021","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104297_bib0051","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104297_bib0052","doi-asserted-by":"crossref","first-page":"a028852","DOI":"10.1101\/cshperspect.a029496","article-title":"Is It possible to develop a \u201cUniversal\u201d influenza virus vaccine? Potential for a universal influenza vaccine","volume":"10","author":"Crowe","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104297_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104297_bib0054","doi-asserted-by":"crossref","first-page":"e01154","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104297_bib0055","doi-asserted-by":"crossref","first-page":"e00352","DOI":"10.1128\/AAC.00352-20","article-title":"A Phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6559","key":"10.1016\/j.ebiom.2022.104297_bib0056","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ebiom.2022.104297_bib0057","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0058","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ebiom.2022.104297_bib0059","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"7853","key":"10.1016\/j.ebiom.2022.104297_bib0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.ebiom.2022.104297_bib0061","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"6505","key":"10.1016\/j.ebiom.2022.104297_bib0062","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"7456","key":"10.1016\/j.ebiom.2022.104297_bib0063","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.ebiom.2022.104297_bib0064","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-Dimer\u2013based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"Dai","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104297_bib0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans","volume":"386","author":"Dickerman","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104297_bib0066","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/v14051020","article-title":"Neuroinvasion and neurotropism by SARS-CoV-2 variants in the K18-hACE2 mouse","volume":"14","author":"Seehusen","year":"2022","journal-title":"Viruses"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:20:03Z","timestamp":1762456803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422004790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":66,"alternative-id":["S2352396422004790"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104297","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104297"}}